Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Spiera

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2020
ReplyRobert Spiera, Lorinda Chung, Tracy Frech, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
Arthritis and Rheumatism|April 29, 2008
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosisPeter K Wung, Troy Anderson, Kevin R Fontaine, et al.
Journal of Scleroderma and Related Disorders|January 8, 2025
Patient perspectives on educational needs in scleroderma-interstitial lung diseaseTina M Savvaides, Thomas A Di Vitantonio, Armani Edgar, et al.
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
The Journal of Rheumatology|March 18, 2011
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosisGunnar Tomasson, Michael Lavalley, Kahraman Tanriverdi, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2020
ReplyRobert Spiera, Lorinda Chung, Tracy Frech, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
Arthritis and Rheumatism|April 29, 2008
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosisPeter K Wung, Troy Anderson, Kevin R Fontaine, et al.
Journal of Scleroderma and Related Disorders|January 8, 2025
Patient perspectives on educational needs in scleroderma-interstitial lung diseaseTina M Savvaides, Thomas A Di Vitantonio, Armani Edgar, et al.
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
The Journal of Rheumatology|March 18, 2011
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosisGunnar Tomasson, Michael Lavalley, Kahraman Tanriverdi, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
Pageof 10